Miranka Wirth1, Sylvia Villeneuve1, Claudia M Haase2, Cindee M Madison1, Hwamee Oh3, Susan M Landau3, Gil D Rabinovici4, William J Jagust3. 1. Helen Wills Neuroscience Institute, University of California, Berkeley. 2. Institute of Personality and Social Research, University of California, Berkeley. 3. Helen Wills Neuroscience Institute, University of California, Berkeley3Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California. 4. Helen Wills Neuroscience Institute, University of California, Berkeley3Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California4Department of Neurology, Memory and Aging Center, University of California, San Francisco.
Abstract
IMPORTANCE: Criteria for preclinical Alzheimer disease (AD) propose β-amyloid (Aβ) plaques to initiate neurodegeneration within AD-affected regions. However, some cognitively normal older individuals harbor neural injury similar to patients with AD, without concurrent Aβ burden. Such findings challenge the proposed sequence and suggest that Aβ-independent precursors underlie AD-typical neurodegenerative patterns. OBJECTIVE To examine relationships between Aβ and non-Aβ factors as well as neurodegeneration within AD regions in cognitively normal older adults. The study quantified neurodegenerative abnormalities using imaging biomarkers and examined cross-sectional relationships with Aβ deposition; white matter lesions (WMLs), a marker of cerebrovascular disease; and cognitive functions. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study in a community-based convenience sample of 72 cognitively normal older individuals (mean [SD] age, 74.9 [5.7] years; 48 women; mean [SD] 17.0 [1.9] years of education) of the Berkeley Aging Cohort. INTERVENTION: Each individual underwent a standardized neuropsychological test session, magnetic resonance imaging, and positron emission tomography scanning. MAIN OUTCOMES AND MEASURES: For each individual, 3 AD-sensitive neurodegeneration biomarkers were measured: hippocampal volume, glucose metabolism, and gray matter thickness, the latter 2 sampled from cortical AD-affected regions. To quantify neurodegenerative abnormalities, each biomarker was age adjusted, dichotomized into a normal or abnormal status (using cutoff thresholds derived from an independent AD sample), and summarized into 0, 1, or more than 1 abnormal neurodegenerative biomarker. Degree and topographic patterns of neurodegenerative abnormalities were assessed and their relationships with cognitive functions, WML volume, and Aβ deposition (quantified using carbon 11-labeled Pittsburgh compound B positron emission tomography). RESULTS: Of our cognitively normal elderly individuals, 40% (n = 29) displayed at least 1 abnormal neurodegenerative biomarker, 26% (n = 19) of whom had no evidence of elevated Pittsburgh compound B retention. In those people who were classified as having abnormal cortical thickness, degree and topographic specificity of neurodegenerative abnormalities were similar to patients with AD. Accumulation of neurodegenerative abnormalities was related to poor memory and executive functions as well as larger WML volumes but not elevated Pittsburgh compound B retention. CONCLUSIONS AND RELEVANCE: Our study confirms that a substantial proportion of cognitively normal older adults harbor neurodegeneration, without Aβ burden. Associations of neurodegenerative abnormalities with cerebrovascular disease and cognitive performance indicate that neurodegenerative pathology can emerge through non-Aβ pathways within regions most affected by AD.
IMPORTANCE: Criteria for preclinical Alzheimer disease (AD) propose β-amyloid (Aβ) plaques to initiate neurodegeneration within AD-affected regions. However, some cognitively normal older individuals harbor neural injury similar to patients with AD, without concurrent Aβ burden. Such findings challenge the proposed sequence and suggest that Aβ-independent precursors underlie AD-typical neurodegenerative patterns. OBJECTIVE To examine relationships between Aβ and non-Aβ factors as well as neurodegeneration within AD regions in cognitively normal older adults. The study quantified neurodegenerative abnormalities using imaging biomarkers and examined cross-sectional relationships with Aβ deposition; white matter lesions (WMLs), a marker of cerebrovascular disease; and cognitive functions. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study in a community-based convenience sample of 72 cognitively normal older individuals (mean [SD] age, 74.9 [5.7] years; 48 women; mean [SD] 17.0 [1.9] years of education) of the Berkeley Aging Cohort. INTERVENTION: Each individual underwent a standardized neuropsychological test session, magnetic resonance imaging, and positron emission tomography scanning. MAIN OUTCOMES AND MEASURES: For each individual, 3 AD-sensitive neurodegeneration biomarkers were measured: hippocampal volume, glucose metabolism, and gray matter thickness, the latter 2 sampled from cortical AD-affected regions. To quantify neurodegenerative abnormalities, each biomarker was age adjusted, dichotomized into a normal or abnormal status (using cutoff thresholds derived from an independent AD sample), and summarized into 0, 1, or more than 1 abnormal neurodegenerative biomarker. Degree and topographic patterns of neurodegenerative abnormalities were assessed and their relationships with cognitive functions, WML volume, and Aβ deposition (quantified using carbon 11-labeled Pittsburgh compound B positron emission tomography). RESULTS: Of our cognitively normal elderly individuals, 40% (n = 29) displayed at least 1 abnormal neurodegenerative biomarker, 26% (n = 19) of whom had no evidence of elevated Pittsburgh compound B retention. In those people who were classified as having abnormal cortical thickness, degree and topographic specificity of neurodegenerative abnormalities were similar to patients with AD. Accumulation of neurodegenerative abnormalities was related to poor memory and executive functions as well as larger WML volumes but not elevated Pittsburgh compound B retention. CONCLUSIONS AND RELEVANCE: Our study confirms that a substantial proportion of cognitively normal older adults harbor neurodegeneration, without Aβ burden. Associations of neurodegenerative abnormalities with cerebrovascular disease and cognitive performance indicate that neurodegenerative pathology can emerge through non-Aβ pathways within regions most affected by AD.
Authors: Bruce Fischl; David H Salat; Evelina Busa; Marilyn Albert; Megan Dieterich; Christian Haselgrove; Andre van der Kouwe; Ron Killiany; David Kennedy; Shuna Klaveness; Albert Montillo; Nikos Makris; Bruce Rosen; Anders M Dale Journal: Neuron Date: 2002-01-31 Impact factor: 17.173
Authors: E C Mormino; J T Kluth; C M Madison; G D Rabinovici; S L Baker; B L Miller; R A Koeppe; C A Mathis; M W Weiner; W J Jagust Journal: Brain Date: 2008-11-28 Impact factor: 13.501
Authors: S M Resnick; J Sojkova; Y Zhou; Y An; W Ye; D P Holt; R F Dannals; C A Mathis; W E Klunk; L Ferrucci; M A Kraut; D F Wong Journal: Neurology Date: 2010-02-10 Impact factor: 9.910
Authors: Rahul S Desikan; Linda K McEvoy; Wesley K Thompson; Dominic Holland; James B Brewer; Paul S Aisen; Reisa A Sperling; Anders M Dale Journal: Arch Neurol Date: 2012-06
Authors: David S Knopman; Clifford R Jack; Heather J Wiste; Stephen D Weigand; Prashanthi Vemuri; Val J Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Michelle M Mielke; Rosebud O Roberts; Bradley F Boeve; Ronald C Petersen Journal: Ann Neurol Date: 2013-02-19 Impact factor: 10.422
Authors: Miranka Wirth; Cindee M Madison; Gil D Rabinovici; Hwamee Oh; Susan M Landau; William J Jagust Journal: J Neurosci Date: 2013-03-27 Impact factor: 6.167
Authors: Miranka Wirth; Hwamee Oh; Elizabeth C Mormino; Candace Markley; Susan M Landau; William J Jagust Journal: Alzheimers Dement Date: 2013-03-07 Impact factor: 21.566
Authors: J Alex Becker; Trey Hedden; Jeremy Carmasin; Jacqueline Maye; Dorene M Rentz; Deepti Putcha; Bruce Fischl; Douglas N Greve; Gad A Marshall; Stephen Salloway; Donald Marks; Randy L Buckner; Reisa A Sperling; Keith A Johnson Journal: Ann Neurol Date: 2011-03-17 Impact factor: 10.422
Authors: Laura E M Wisse; Nirali Butala; Sandhitsu R Das; Christos Davatzikos; Bradford C Dickerson; Sanjeev N Vaishnavi; Paul A Yushkevich; David A Wolk Journal: Neurobiol Aging Date: 2015-09-07 Impact factor: 4.673
Authors: Clifford R Jack; David S Knopman; Gaël Chételat; Dennis Dickson; Anne M Fagan; Giovanni B Frisoni; William Jagust; Elizabeth C Mormino; Ronald C Petersen; Reisa A Sperling; Wiesje M van der Flier; Victor L Villemagne; Pieter J Visser; Stephanie J B Vos Journal: Nat Rev Neurol Date: 2016-01-18 Impact factor: 42.937
Authors: Mohamad Habes; Guray Erus; Jon B Toledo; Tianhao Zhang; Nick Bryan; Lenore J Launer; Yves Rosseel; Deborah Janowitz; Jimit Doshi; Sandra Van der Auwera; Bettina von Sarnowski; Katrin Hegenscheid; Norbert Hosten; Georg Homuth; Henry Völzke; Ulf Schminke; Wolfgang Hoffmann; Hans J Grabe; Christos Davatzikos Journal: Brain Date: 2016-02-24 Impact factor: 13.501
Authors: Pauline Maillard; Evan Fletcher; Baljeet Singh; Oliver Martinez; David K Johnson; John M Olichney; Sarah T Farias; Charles DeCarli Journal: Neurology Date: 2019-04-05 Impact factor: 9.910
Authors: Murat Bilgel; Rebecca L Koscik; Yang An; Jerry L Prince; Susan M Resnick; Sterling C Johnson; Bruno M Jedynak Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Anna Caroli; Annapaola Prestia; Samantha Galluzzi; Clarissa Ferrari; Wiesje M van der Flier; Rik Ossenkoppele; Bart Van Berckel; Frederik Barkhof; Charlotte Teunissen; Anders E Wall; Stephen F Carter; Michael Schöll; Il Han Choo; Timo Grimmer; Alberto Redolfi; Agneta Nordberg; Philip Scheltens; Alexander Drzezga; Giovanni B Frisoni Journal: Neurology Date: 2015-01-07 Impact factor: 9.910